Genmab A/S Logo

Genmab A/S (GNMSF)

OTC

Currency in USD
376.00
-20.97 (-5.28%)

Closed

Oct 6, 2026

Day's Range

376.00
384.00

52 wk Range

232.34
396.97

Overview - GNMSF - Genmab A/S

Key Statistics

Valuation

Enterprise Value

24.83B

P/E (Trailing)

‪27.43‬

P/E (Forward)

‪25.09‬

PEG Ratio

‪-2.98‬

Price / Sales (TTM)

‪5.16‬

Price / Book

‪3.47‬

EV / EBITDA

‪18.03‬

Profitability

Gross Margin

‪92.72%‬

Profit Margin

‪19.07%‬

Operating Margin

‪35.23%‬

Return on Assets

‪8.78%‬

Return on Equity

‪13.99%‬

Ownership

Shares Outstanding

61.43M

Float

58.96M

Held by Insiders

‪1.11%‬

Held by Institutions

‪42.62%‬

Price stats

Beta

‪0.69‬

50-Day Avg

‪315.77‬

200-Day Avg

‪294.43‬

Dividends

Payout Ratio

‪0.00%‬

Shariah Compliance

Not Shariah Compliant

Report Date: Feb 16, 2025

Screened by Zoya using the AAOIFI methodology.

News Teaser - GNMSF - Genmab A/S

News & Analysis

View all news

Market Cap - GNMSF - Genmab A/S

Peers - GNMSF - Genmab A/S

Peer Comparison

Compared with companies in Biotechnology listed on OTC.

Profile Summary - GNMSF - Genmab A/S

About

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human antibody technologies to create differentiated products that address…

SectorHealthcare
IndustryBiotechnology
Employees3.08K
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.